Monte Rosa Therapeutics, Inc.
NASDAQ:GLUEBiotechnology
-$0.26 today
- Market cap
- $775.03M
- Beta
- 1.60
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.98
Volume 1.26M
Average 1.02M
GLUE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Monte Rosa Therapeutics, Inc.NASDAQ: GLUE
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$44.5M, compared with $46.89M a year earlier. Trailing-twelve-month net income was -$130.01M. Over 3 fiscal years it compounded at -29.1% a year.
Context
- Net income amounted to 31.2% of revenue in FY2025, down 64.9 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$57.83M (+49.7%) for the fiscal year ending Dec 2026, a step up from the -46.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$44.5M-3.5% QoQ
- Last fiscal yearDec 2025
- -$38.63M-46.9% YoY
- LTMMar 2026
- -$130.01M-2213.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -194.9% | +236.1% | +431.0 pp |
| 1 year | -46.9% | +49.7% | +96.6 pp |
| 3-year CAGR | -29.1% | +60.6% | +89.7 pp |
| 5-year CAGR | +29.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (38.63M) USD
- Year-over-year change
- +46.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (38.63M) | +46.9% |
| FY2024 | 2024-12-31 | (72.7M) | +46.3% |
| FY2023 | 2023-12-31 | (135.35M) | -24.7% |
| FY2022 | 2022-12-31 | (108.5M) | -46.7% |
| FY2021 | 2021-12-31 | (73.96M) | — |
Net Income vs competitors
How GLUE compares with its peers on the latest reported figures
- GLUE's LTM Mar 2026 net income of $130.01M is the 3rd largest of the 4 companies compared; the peer median is $103.8M.
- Its year-over-year change of -2213.0% is the lowest of 4, against a peer median of +220.5%.
- Net income amounts to 302.7% of revenue for GLUE, versus a peer median of 247.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $294.88M | +220.5% | +13.6% | 42.0% | |
| LTM Mar 2026 | $221.3M | +374.9% | -34.1% | 247.5% | |
| LTM Mar 2026 | $130.01M | -2213.0% | -29.1% | 302.7% | |
| LTM Mar 2026 | $103.8M | +0.5% | -6.4% | 297.8% | |
| Peer median (excluding GLUE) | $103.8M | +220.5% | -6.4% | 247.5% | |
Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.96M) | (108.5M) | (135.35M) | (72.7M) | (38.63M) |
| Depreciation & Amortization | 2.13M | 3.75M | 6.22M | 8.12M | 8.36M |
| Deferred Income Tax | 17K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.2M | 11.66M | 16.67M | 18.13M | 18.87M |
| Change in Working Capital | 6.29M | (2.13M) | 72.47M | 91.4M | (9.19M) |
| Accounts Receivables | 0 | (187) | 1.9M | 332K | (7M) |
| Inventory | 0 | 187 | 0 | 0 | 0 |
| Accounts Payables | (706K) | (744K) | 5.76M | 6.25M | (13.71M) |
| Other Working Capital | 6.99M | (1.39M) | 64.81M | 84.81M | 11.52M |
| Other Non-Cash Items | 960K | 2.76M | (3.81M) | (2.95M) | (2.2M) |
| Operating Cash Flow | (59.36M) | (92.47M) | (43.8M) | 42M | (22.8M) |
| Capital Expenditures | (9.73M) | (12.91M) | (19.04M) | (3.99M) | (4.7M) |
| Acquisitions (Net) | 79K | 109K | 62K | 0 | 0 |
| Purchases of Investments | 0 | (384.42M) | (103.15M) | (230.36M) | (376.68M) |
| Sales of Investments | 0 | 178M | 210.93M | 189.9M | 279.54M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (9.65M) | (219.22M) | 88.8M | (44.45M) | (101.83M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 237.75M | 20.06M | 27.49M | 944K | 30.35M |
| Common Stock Repurchased | 0 | 0 | 0 | (641K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.19M) | 411K | 0 | 98.59M | 0 |
| Financing Cash Flow | 377.56M | 20.47M | 27.49M | 98.89M | 30.35M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 308.55M | (291.22M) | 72.49M | 96.44M | (94.28M) |
| Free Cash Flow | (69.1M) | (105.38M) | (62.84M) | 38.01M | (27.5M) |
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
Intrinsic Alpha fair value
Locked
Current Price
$9.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.